Looks like you clickedhttps://www.globenewswire.com/news-release/2023/12/11/2793570/0/en/New-Data-Presented-at-ASH-from-the-Phase-3-GLOW-Study-Show-Fixed-Duration-First-Line-Treatment-with-IMBRUVICA-ibrutinib-Plus-Venetoclax-Demonstrated-an-Overall-Survival-Rate-of-Mor.html
If you do not want to visit that page, you can close this browser tab.
